Table III.
Best anatomic clinical response (computed tomography) by lymphoma subtype.
| Subtype | 4 mg/kg (MTD) | All |
|---|---|---|
| FL | n = 16 | n = 21 |
| ORR, n (%) | 6 (37·5) | 7 (33·3) |
| CR, n (%) | 1 (6·3) | 1 (4·8) |
| PR, n (%) | 5 (31·3) | 6 (28·6) |
| SD, n (%) | 7 (43·8) | 11 (52·4) |
| PD, n (%) | 3 (18·8) | 3 (14·3) |
| NE, n (%) | – | – |
| DLBCL | n = 26 | n = 34 |
| ORR, n (%) | 2 (7·7) | 4 (11·8) |
| CR, n (%) | 1 (3·8) | 2 (5·9) |
| PR, n (%) | 1 (3·8) | 2 (5·9) |
| SD, n (%) | 8 (30·8) | 11 (32·4) |
| PD, n (%) | 12 (46·2) | 15 (44·1) |
| NE, n (%) | 4 (15·4) | 4 (11·8) |
| MALT | n = 7 | n = 7 |
| ORR, n (%) | 3 (42·9) | 3 (42·9) |
| CR, n (%) | 1 (14·3) | 1 (14·3) |
| PR, n (%) | 2 (28·6) | 2 (28·6) |
| SD, n (%) | 1 (14·3) | 1 (14·3) |
| PD, n (%) | 2 (28·6) | 2 (28·6) |
| NE, n (%) | 1 (14·3) | 1 (14·3) |
| MCL | n = 8 | n = 12 |
| ORR, n (%) | – | – |
| CR, n (%) | – | – |
| PR, n (%) | – | – |
| SD, n (%) | 3 (37·5) | 5 (41·7) |
| PD, n (%) | 4 (50·0) | 5 (41·7) |
| NE, n (%) | 1 (25·0) | 2 (16·7) |
| HL | n = 34 | n = 37 |
| ORR, n (%) | 4 (11·8) | 5 (13·5) |
| CR, n (%) | – | – |
| PR, n (%) | 4 (11·8) | 5 (13·5) |
| SD, n (%) | 11 (32·4) | 12 (32·4) |
| PD, n (%) | 13 (38·2) | 14 (37·8) |
| NE, n (%) | 6 (17·6) | 6 (16·2) |
CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HL, Hodgkin lymphoma; MALT, mucosa-associated lymphatic tissue lymphoma; MCL, mantle cell lymphoma; MTD, maximum tolerated dose; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.